Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

“Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive disease [that] sadly impairs the quality of life, functional capacity and health status of patients, as described by ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to acoramidis (Beyonttra) for adult ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

This would be with respect to the advancement of nexiguran ziclumeran [nex-z] as a treatment option for patients with ATTR Amyloidosis with cardiomyopathy [ATTR-CM]. The use of this drug ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...

ATTRv amyloidosis predominantly manifests as polyneuropathy (ATTRv-PN), which can lead to nerve damage, or cardiomyopathy (ATTRv-CM), which can lead to heart failure. Some individuals without the ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...